IP Library Granted Patent US 9,296,795
Granted Patent B2
US 9,296,795 · App. 10/548,507 · Granted Mar 29, 2016

Polysaccharide-staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections

Inventors: Viliam Pavliak (Montebello, NY); Steven Morris Baker (Highland Mills, NY); Subramonia Padmanaba Pillai (Pomona, NY)
Assignees: WYETH HOLDINGS, LLC.; INHIBITEX, INC.
C07K14/31A61K39/085A61K39/092A61K47/4823A61K47/4833A61K2039/6068
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,296,795
App. No.
10/548,507
Granted
Mar 29, 2016
Kind
B2
Abstract

Immunogenic polysaccharide-protein conjugates having a polysaccharide antigen (or its oligosaccharide fragment representing one or more antigenic epitopes) derived from a nosocomial pathogen conjugated to a staphylococcal surface adhesin carrier protein are used in immunogenic compositions to elicit antibody responses to both the polysaccharide antigen and the staphylococcal surface adhesion carrier protein. Such immunogenic compositions are used to immunize against diseases caused by Staphylococcal aureus, Staphylococcal epidermidis or other nosocomial pathogens.

Claims (32)

1. An immunogenic polysaccharide-protein conjugate, comprising: at least one polysaccharide antigen derived from a nosocomial pathogen and at least one staphylococcal surface adhesin carrier protein,

wherein the conjugate generates specific antibodies to both the polysaccharide antigen and the staphylococcal surface adhesin carrier protein, and

wherein the polysaccharide antigen is an antigen from coagulase-negative staphylococci (CoNS), wherein the CoNS is Staphylococcus epidermidis ( S. epidermidis ).

2. An immunogenic polysaccharide-protein conjugate, comprising: an oligosaccharide fragment representing one or more antigenic epitopes of at least one polysaccharide antigen derived from a nosocomial pathogen and at least one staphylococcal surface adhesin carrier protein,

wherein the conjugate generates specific antibodies to both the polysaccharide antigen and the staphylococcal surface adhesin carrier protein, and

wherein the polysaccharide antigen is an antigen from coagulase-negative staphylococci (CoNS), wherein the CoNS is Staphylococcus epidermidis ( S. epidermidis ).

3. The conjugate of claim 1 , wherein the polysaccharide antigen is polysaccharide intercellular adhesin (PIA), polysaccharide adhesin (PS/A), poly-N-succinyl β-1-6-glucosamine (PNSG), or poly-N-acetyl β-1-6-glucosamine (PNAG), expressed by S. epidermidis.

4. The conjugate of claim 1 , wherein the staphylococcal surface adhesin carrier protein is selected from the group consisting of fibrinogen-binding protein, fibronectin-binding protein, collagen-binding protein, vitronectin-binding protein and combinations thereof.

5. The conjugate of claim 4 , wherein the staphylococcal surface adhesin carrier protein is the fibronectin-binding protein of S. aureus.

6. The conjugate of claim 4 , wherein the staphylococcal surface adhesin carrier protein is the collagen-binding protein of S. aureus.

7. The conjugate of claim 4 , wherein the staphylococcal surface adhesin carrier protein is the vitronectin-binding protein of S. aureus.

8. The conjugate of claim 1 , wherein the polysaccharide antigen is conjugated to the staphylococcal surface adhesin carrier protein through a linker.

9. The conjugate of claim 8 , wherein the linker is 3-(2-pyridyldithio)-propionyl hydrazide (PDPH).

10. An immunogenic composition comprising the conjugate of claim 1 in an immunologically acceptable carrier or diluent.

11. The immunogenic composition of claim 10 , further comprising an adjuvant.

12. The conjugate of claim 2 , wherein the polysaccharide antigen is polysaccharide intercellular adhesin (PIA), polysaccharide adhesin (PS/A), poly-N-succinyl β-1-6-glucosamine (PNSG), or poly-N-acetyl β-1-6-glucosamine (PNAG), expressed by S. epidermidis.

13. The conjugate of claim 2 , wherein the staphylococcal surface adhesin carrier protein is selected from the group consisting of fibrinogen-binding protein, fibronectin-binding protein, collagen-binding protein, vitronectin-binding protein and combinations thereof.

14. The conjugate of claim 13 , wherein the staphylococcal surface adhesin carrier protein is the fibronectin-binding protein of S. aureus.

15. The conjugate of claim 13 , wherein the staphylococcal surface adhesin carrier protein is the collagen-binding protein of S. aureus.

16. The conjugate of claim 13 , wherein the staphylococcal surface adhesin carrier protein is the vitronectin-binding protein of S. aureus.

17. The conjugate of claim 2 , wherein the polysaccharide antigen is conjugated to the staphylococcal surface adhesin carrier protein through a linker.

18. The conjugate of claim 17 , wherein the linker is 3-(2-pyridyldithio)propionyl hydrazide (PDPH).

19. An immunogenic composition comprising the conjugate of claim 2 in an immunologically acceptable carrier or diluent.

20. The immunogenic composition of claim 19 , further comprising an adjuvant.

21. An immunogenic polysaccharide-protein conjugate, comprising: at least one polysaccharide antigen derived from a nosocomial pathogen and at least one staphylococcal surface adhesin carrier protein,

wherein the conjugate generates specific antibodies to both the polysaccharide antigen and the staphylococcal surface adhesin carrier protein, and

wherein the polysaccharide antigen is an antigen from Staphylococcus aureus ( S. aureus ), or coagulase-negative staphylococci (CoNS), wherein the CoNS is Staphylococcus epidermidis ( S. epidermidis ) and

wherein the polysaccharide antigen is polysaccharide intercellular adhesin (PIA), polysaccharide adhesin (PS/A), poly-N-succinyl β-1-6-glucosamine (PNSG), or poly-N-acetyl β-1-6-glucosamine (PNAG), expressed by S. aureus or S. epidermidis.

22. An immunogenic polysaccharide-protein conjugate, comprising: an oligosaccharide fragment representing one or more antigenic epitopes of at least one polysaccharide antigen derived from a nosocomial pathogen and at least one staphylococcal surface adhesin carrier protein,

wherein the conjugate generates specific antibodies to both the polysaccharide antigen and the staphylococcal surface adhesin carrier protein, and

wherein the polysaccharide antigen is an antigen from Staphylococcus aureus ( S. aureus ) or coagulase-negative staphylococci (CoNS), wherein the CoNS is Staphylococcus epidermidis ( S. epidermidis ); and

wherein the polysaccharide antigen is polysaccharide intercellular adhesin (PIA), polysaccharide adhesin (PS/A), poly-N-succinyl β-1-6-glucosamine (PNSG), or poly-N-acetyl β-1-6-glucosamine (PNAG), expressed by S. aureus or S. epidermidis.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED AT REEL: 016846 FRAME: 0751. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jan 12, 2016
From: PAVLIAK, VILIAM; BAKER, STEVEN MORRIS; PILLAI, SUBRAMONIA PADMANABA; PATTI, JOSEPH M.; PRATER, BRADLEY D.
To: WYETH HOLDINGS CORPORATION; INHIBITEX, INC.
Reel/Frame 037485/0873 →
ASSIGNMENT OF 50% OF THE RIGHT, TITLE AND INTEREST Recorded Dec 12, 2014
From: WYETH HOLDINGS LLC
To: INHIBITEX, INC.
Reel/Frame 034627/0573 →
CHANGE OF NAME Recorded Oct 16, 2014
From: WYETH HOLDINGS CORPORATION
To: WYETH HOLDINGS LLC
Reel/Frame 034011/0861 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 1, 2011
From: INHIBITEX, INC.
To: WYETH HOLDINGS CORPORATION
Reel/Frame 026367/0580 →
Continuity (2)
Provisional Application 60452728 · Mar 7, 2003
Related Publication 20070087014A1 · Apr 19, 2007